Table 9.
Result of success factors of new drug clinical trials (Phase 2 – NME vs. Biologicals)
| Variable | NME (Phase 2) | Biologicals (Phase 2) | ||||||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Experience |
0.999*** (0.000) |
0.999*** (0.000) |
0.999*** (0.000) |
0.999*** (0.000) |
0.999* (0.000) |
1.000* (0.000) |
0.999* (0.000) |
0.999* (0.000) |
| Success ratio |
31.877*** (4.443) |
32.023*** (4.462) |
32.067*** (4.456) |
32.019*** (4.450) |
36.144*** (11.381) |
36.145*** (11.483) |
35.735*** (11.230) |
35.984*** (11.302) |
| Duration |
1.000*** (0.000) |
1.000*** (0.000) |
1.000*** (0.000) |
1.000*** (0.000) |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
| Relationship type |
1.041 (0.112) |
1.001 (0.087) |
1.206 (0.348) |
1.086 (0.270) |
||||
| Nation |
0.671 (0.209) |
0.941 (0.118) |
0.635 (0.442) |
0.851 (0.339) |
||||
| Continent |
1.445 (0.464) |
1.012 (0.136) |
1.235 (0.966) |
0.933 (0.442) |
||||
| N | 5981 | 5981 | 5981 | 5981 | 961 | 961 | 961 | 961 |
| Pseudo-R2 | 0.1366 | 0.1363 | 0.1363 | 0.1363 | 0.1955 | 0.1948 | 0.1948 | 0.1947 |
| Prob > χ2 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Log-likelihood | − 2314.360 | − 2315.237 | − 2315.119 | − 2315.233 | − 312.307 | − 312.584 | − 312.553 | − 312.627 |
***p < 0.01, **p < 0.05, *p < 0.1